In particular, pemigatinib and futibatinib were approved for the treatment of unresectable, previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA) with FGFR2 fusion [152,153]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.